Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
StemCells, Inc.
ClinicalTrials.gov Identifier:
NCT01632527
First received: June 21, 2012
Last updated: July 24, 2014
Last verified: July 2014
  Purpose

The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of unilateral subretinal transplantation of HuCNS-SC cells in subjects with geographic atrophy secondary to age-related macular degeneration.


Condition Intervention Phase
Age Related Macular Degeneration
Macular Degeneration
AMD
Drug: HuCNS-SC cells
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase I/II Study of the Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

Resource links provided by NLM:


Further study details as provided by StemCells, Inc.:

Primary Outcome Measures:
  • Number of subjects with adverse events [ Time Frame: One year following transplant surgery ] [ Designated as safety issue: Yes ]
    Descriptive analysis of frequency and types of adverse events experienced by each subject during the study period.


Secondary Outcome Measures:
  • Assessment of visual function changes from baseline [ Time Frame: At frequent intervals for one year following transplantation ] [ Designated as safety issue: No ]
    Assessments will include BCVA by the E-ETDRS acuity test, fluorescein angiography and fundus photography, spectral domain ocular coherence tomography (OCT), microperimetry, multifocal electroretinography, contrast sensitivity, and a standardized questionnaire of visual function.


Enrollment: 15
Study Start Date: June 2012
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HuCNS-SC
HuCNS-SC cells
Drug: HuCNS-SC cells
HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
Other Name: Human Central Nervous System Stem Cells

Detailed Description:

This study is an open-label dose-escalation investigation of the safety and preliminary efficacy of unilateral subretinal transplantation of HuCNS-SC cells in subjects with Geographic Atrophy secondary to Age-Related Macular Degeneration (AMD). Subjects will be enrolled based on specific inclusion/exclusion criteria and evaluated at regular post transplant intervals. The investigation will be divided into two sequential cohorts. Subjects will be enrolled into each cohort based on best-corrected visual acuity (BCVA) visual acuity as determined by the Electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS) acuity test. BCVA of less than or equal to 20/400 in the Study Eye will be enrolled in Cohort I. Subjects with BCVA of 20/320 to 20/100 in the Study Eye will be enrolled in Cohort II. Cohort I will consist of four subjects who will undergo transplant with 200,000 cells followed by four subjects who will undergo transplant with 1 million cells. Cohort II will consist of 7 subjects who will undergo transplant with 1 million cells. An independent Data Monitoring Committee (DMC) will review accruing safety data for all subjects.

HuCNS-SC cells will be transplanted by a board-certified vitreoretinal surgeon. The transplantation will be conducted in the eye with the inferior best-corrected visual acuity (BCVA) (i.e., the Study Eye). Only the Study Eye will undergo transplantation. The HuCNS-SC cells will be administered into the subretinal space through a standard surgical approach.

Immunosuppressive agents will be administered orally to all subjects for a period of three months after surgery.

Subjects will be monitored frequently for a total of one year after HuCNS-SC cell transplantation. An additional four years of monitoring will be conducted in a separate follow-up study that will commence with the termination visit of the Phase I/II investigation. The follow-up study will be conducted as a separate investigation.

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of age-related macular degeneration with geographic atrophy (GA)
  • Only patients with a specific degree and extent of GA will be eligible
  • Subjects with best-corrected visual acuity (BCVA) of less than or equal to 20/400 in the Study Eye will be enrolled in Cohort I. Subjects with BCVA of 20/320 to 20/100 in the Study Eye will be enrolled in Cohort II
  • No prior or current choroidal neovascularization in either eye
  • Must have adequate care-giver support and access to medical care in the local community
  • Able to provide written informed consent prior to any study related procedures
  • Agree to comply in good faith with all conditions of the study and to attend all required study visits

Exclusion Criteria:

  • Prior vitreal or retinal surgery
  • Glaucoma
  • Atrophic macular disease of any other cause
  • Diabetic retinopathy or diabetic macular edema in either eye
  • Previous organ, tissue or bone marrow transplantation
  • Previous participation in a gene transfer or a cell transplant trial
  • Autoimmune disease
  • Allergy to tacrolimus, mycophenolate mofetil (MMF), scopolamine, Cyclogyl, Moxifloxacin, or Gatifloxacin
  • Current or prior malignancy (or is on chemotherapy)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01632527

Locations
United States, California
Retina-Vitreaous Associates Medical Group
Los Angeles, California, United States, 90211
Byers Eye Institute at Stanford, Stanford Hospital and Clinics
Palo Alto, California, United States, 94303
United States, New York
New York Eye and Ear Infirmary
New York, New York, United States, 10003
United States, Texas
Retina Research Institute of Texas
Abilene, Texas, United States, 79606
Retina Foundation of the Southwest
Dallas, Texas, United States, 75231
Sponsors and Collaborators
StemCells, Inc.
Investigators
Study Director: Stephen Huhn, M.D. StemCells, Inc.
  More Information

Additional Information:
No publications provided

Responsible Party: StemCells, Inc.
ClinicalTrials.gov Identifier: NCT01632527     History of Changes
Other Study ID Numbers: StemCells CL-N01-AMD
Study First Received: June 21, 2012
Last Updated: July 24, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by StemCells, Inc.:
Age-Related Macular Degeneration
Dry AMD with GA
Geographic Atrophy of Age-Related Macular Degeneration
Stem Cell Transplantation
Stem Cell transplant
Stem cells for AMD
Human neural stem cells
multipotent stem cells
Macular Degeneration
Dry AMD
Human central nervous system stemcells
dry age-related macular degeneration

Additional relevant MeSH terms:
Macular Degeneration
Geographic Atrophy
Retinal Degeneration
Retinal Diseases
Eye Diseases

ClinicalTrials.gov processed this record on August 27, 2014